Endocrine Abstracts

Background: Metabolic syndrome (MetS) is a clustering of metabolic and cardiovascular risk factors, with insulin resistance being one of the main components. In male, MetS is also associated to hypogonadotropic hypogonadism. Lifestyle modifications (e.g. physical activity) could prevent or considerably reduce MetS progression, however the ability to perform physical activity is often impaired in MetS subjects.Aim: Considering the known trophic role of T ...

Pathologies of the female reproductive system, characterized by chronic pain, are frequent and it has been hypothesized that inflammation may play an essential role in their pathogenesis. It is known that androgens, including dihydrotestosterone (DHT), have shown immunomodulatory effects in experimental models of chronic inflammation. The aim of this study was to evaluate the immunomodulatory effects of DHT in smooth muscle cells (rSMCs) isolated from vagina of intact Sprague-...

Introduction: In humans, prostate PDE5 expression was prominently localized in the endothelial and smooth muscle cells of the vascular bed, suggesting a possible action of PDE5 inhibitors on prostate blood flow.Aim: To investigate PDE5 expression in human and rat lower urinary tract (LUT) tissues and determine the effects of PDE5 inhibition with tadalafil on prostatic blood perfusion.Main outcome measures: Human vesicular-deferenti...

Introduction: Several studies suggested a direct relationship between metabolic syndrome (MetS) and increased risk of benign prostatic hyperplasia (BPH). An inflammatory component, mainly mediated by IL-8, has been proposed as the primary link between MetS and BPH pathogenesis. MetS, is often associated with testosterone (T) deficiency and an imbalance between the androgen and estrogen ratio characterizes BPH patients.Methods: We investigated the effects...

Metabolic syndrome (MetS) is a clustering of cardio-metabolic risk factors (hyperglycemia, hypertension, dyslipidemia, visceral fat accumulation) that is also associated with hypogonadism and erectile dysfunction (ED). The study was aimed at clarifying the relationships among MetS, hypogonadism, and ED, we developed an animal model of MetS.Methods: Male rabbits fed a high-fat diet (HFD), with or without testosterone (T) supplementation, were compared wit...

In male, lower urinary tract symptoms (LUTS) have been associated, beside benign prostatic hyperplasia, to some unexpected co-morbidities, such as hypogonadism, obesity and metabolic syndrome, which are essentially characterized by an unbalance between circulating androgens and estrogens. Within the bladder, LUTS have been linked to overactivity of the RhoA/ROCK pathway. Here we investigate the effects of changing sex steroids on bladder smooth muscle. The effects of androgens...

One of the proposed mechanisms responsible for Diabetes mellitus (DM)-associated erectile (ED) dysfunction is overactivity of RhoA/ROCK signalling. Because statins may decrease RhoA activation, we investigated whether atorvastatin ameliorated DM-induced ED in alloxan-treated (100 mg/kg) rabbits (in vitro studies) and streptozotocin-treated (STZ, 50 mg/kg) rats (in vivo studies). A subgroup of diabetic animals received atorvastatin 5 mg/kg per daily 2 weeks before...

A previous study demonstrate that chronic tadalafil administration (2 mg/kg per day) was able to prevent some, but not all, penile alterations induced by long-term (3 months) bilateral cavernous neurotomy (BCN) in the rat. In particular, in vitro acetylcholine responsiveness and reduced eNOS and nNOS expression were not preserved, while PDE5 down-regulation, along with muscle/fiber ratio and hypoxygenation (hypoxyprobe) were significantly restored by chronic tadalafil (...

Epididymis (epi) is a sex steroid-sensitive duct provided with spontaneous motility, allowing sperm transport. We previously demonstrated that human epi expresses a high abundance of mRNA for ER-alpha and ER-beta. We demonstrated that in epi estrogens up-regulate either oxytocin (OT) responsiveness, acting at the receptor level, and responsiveness to endothelin-1 (ET-1), another well-known stimulator of epididymal motility. However, we did not find any significant change eithe...

BXL-628 is a non-hypercalcemic calcitriol analog successfully tested in a phase IIa trial for benign prostate hyperplasia therapy. Because part of low urinary tract symptoms (LUTS) are generated by overactive bladder (OAB) and bladder expresses the calcitriol receptor (VDR), we investigated the BXL-628 effects on bladder contractility and RhoA/ROK signalling activated in OAB, by in vivo (2-weeks; 30 mcg/Kg, Sprague-Dawley, SD, and spontaneously hypertensive rats, SHR) a...